Mucinous advanced epithelial ovarian carcinoma: Clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience

Annals of Oncology

Volumn 21, Issue 12, 2010, Pages 2377-2381

  Alexandre, J ^a   Ray Coquard, I ^b   Selle, F ^c   Floquet, A ^d   Cottu, P ^e   Weber, B ^f   Falandry, C ^g   Lebrun, D ^h   Pujade Lauraine, E ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CENTRE LÉON BÉRARD   (France)

^c HÔPITAL TENON   (France)

^d INSTITUT BERGONIÉ   (France)

^e INSTITUT CURIE   (France)

^f CENTRE ALEXIS VAUTRIN   (France)

^g CENTRE HOSPITALIER LYON SUD   (France)

^h INSTITUT JEAN GODINOT   (France)

Author keywords

Carboplatin; Chemoresistant; Epithelial ovarian tumor; Mucinous; Paclitaxel

Indexed keywords

CARBOPLATIN; EPIRUBICIN; GEMCITABINE; HEMOGLOBIN; PACLITAXEL; PLATINUM; TOPOTECAN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER STAGING; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MUCINOUS ADVANCED EPITHELIAL OVARY CARCINOMA; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; VISCERAL METASTASIS;

EID: 78649486193     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq257     Document Type: Article

References (21)

1. Chan JK, Teoh D, Hu JM, et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 2008; 109: 370-376.
2. Vergote I, De drabanter J, Fyles A, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001; 357: 176-182.
3. Omura GA, Brady MF, Homesley HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991; 9: 1138-1150.
4. Teramukai S, Ochiai K, Tada H, Fukushima M. PIEPOC: a new prognostic index for advanced epithelial ovarian cancer-Japan Multinational Trial Organization OC01-01. J Clin Oncol 2007; 25: 3302-3306.
5. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
6. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000; 92: 699-708.
7. Vergote I, Trope CG, Amant F, et al. EORTC-GCG/NCIC-CTG randomized trial comparing primary debulking surgery with neoadjuvant chemotherapy in stageIIIC-IV ovarian, fallopian tube and peritoneal cancer. In 12th Meeting International Gynecologic Cancer Society (Abstr). Bangkok, Thailand 25-28 October 2008.
8. Du Bois A, Weber B, Rochon J, et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol 2006; 24: 1127-1135.
9. Herrstedt J, Huober J, Priou F, et al. A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): gemcitabine-paclitaxel-carboplatin (TCG) versus paclitaxel-carboplatin (TC) as first-line treatment of ovarian cancer (OC): survival of FIGO stage I-IIA patients. J Clin Oncol 2009; 27 (Suppl 2): 18s.
10. Pfisterer J, Weber B, Reuss A, et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 2006; 98: 1036-1045.
11. Ray-Coquard I, Paraiso D, Guastalla JP, et al. Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group. Br J Cancer 2007; 97: 1200-1205.
12. Trédan O, Geay JF, Touzet S, et al. Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. Ann Oncol 2007; 18: 256-262.
13. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Offset publication 40. Geneva, Switzerland: World Health Organization 1979.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
15. Hess V, A'Hern R, Nasiri N, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 2004; 22: 1040-1044.
16. Pectasides D, Fountzilasb G, Aravantinos G, et al. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 2005; 97: 436-441.
17. Tian C, Markman M, Zaino R, et al. CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers. Cancer 2009; 115: 1395-1403.
18. Trimbos JB, Parmar M, Vergote I, et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant Chemotherapy in Ovarian Neoplasm Trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003; 95: 105-112.
19. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008; 26: 5284-5293.
20. Gemignani ML, Schlaerth AC, Bogomolniy F, et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 2003; 90: 378-381.
21. Marquez RT, Baggerly KA, Patterson AP, et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 2005; 11: 6116-6126.